Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The UK Veterinary Biologics Market was valued at $75.01 Million in 2025 and projected to reach to $99 Million by 2030, representing a compound annual growth rate of 5.7%. The UK veterinary biologics market is poised for sustained growth at a CAGR of 5.7% through 2030, outpacing the global average of 5.2%.

UK Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Veterinary Biologics Market Trends and Insights

  • The UK market benefits from strong regulatory frameworks, advanced veterinary infrastructure, and increasing investment in animal health innovation.
  • The UK's position as a leader in European veterinary research and development continues to drive demand for biologics across companion animal, livestock, and equine segments. Growth in the UK veterinary biologics sector is underpinned by rising pet ownership, heightened biosecurity concerns in livestock farming, and regulatory support for novel therapeutic solutions.
  • The UK market reflects growing adoption of immunological and biological treatments, supported by veterinary professionals' commitment to precision medicine in animal care.
  • Between 2025 and 2030, the UK is expected to see accelerated uptake of advanced biologics, driven by both preventive and therapeutic applications across diverse animal populations..

Key Market Statistics

  • CAGR (2025-2030) 5.7% CAGR
  • Market Size, 2025 ~USD 75.01 Million
  • Forecast, 2030 ~USD 99 Million
  • Country UK

UK Veterinary Biologics Market Overview

Market Valuation :

The UK veterinary biologics market is valued at $75.01 million in 2025, with projections reaching $99 million by 2030, demonstrating steady growth in the animal health sector.

Regulatory Excellence :

The UK benefits from stringent regulatory frameworks and compliance standards that ensure high-quality veterinary biologics, positioning it as a trusted market for innovative animal health solutions.

R&D Leadership :

The UK maintains a strong position as a leader in European veterinary research and development, with significant investment in advancing biologics innovation and therapeutic development.

Infrastructure Advantage :

Advanced veterinary infrastructure and established distribution networks across the UK support efficient market penetration and adoption of biologics among veterinary practitioners.

UK Veterinary Biologics Market Dynamics

  • This growth is driven by increasing awareness of preventive animal healthcare, rising pet ownership, and growing livestock disease management concerns.
  • The UK's robust regulatory environment and investment in veterinary innovation create a favorable ecosystem for market expansion. Key drivers include the adoption of advanced biologics for companion animals and livestock, strengthening biosecurity measures post-pandemic, and collaboration between UK research institutions and pharmaceutical companies.
  • The market will benefit from emerging therapies, immunological advances, and increased government support for animal health initiatives, positioning the UK as a significant growth hub within the European veterinary biologics landscape..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • The UK veterinary biologics market is valued at $75.01 million in 2025 and will reach $99 million by 2030, growing at 5.7% CAGR.
    • The UK's robust regulatory environment and advanced veterinary infrastructure position it as a key hub for biologics innovation and adoption in Europe.
    • Rising pet ownership and biosecurity concerns in UK livestock farming are primary drivers of demand for biological therapeutics and vaccines.
    • The UK market is characterized by increasing adoption of precision medicine approaches and immunological treatments across companion, livestock, and equine sectors.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    UK Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    UK: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS4.995.115.245.395.555.745.966.183.4
    VETERINARY DIAGNOSTIC LABS29.9730.931.9433.1134.3935.8337.4439.164.2
    VETERINARY HOSPITALS & CLINICS85.7789.894.2499.19104.6110.64117.39124.685.8
    TOTAL120.73125.81131.41137.68144.55152.2160.79170.035.3

    Target Audience

    • Veterinary Pharmaceutical Companies : Manufacturers and distributors need UK-specific market data to develop localized product strategies, identify distribution partnerships, and optimize market entry approaches.
    • Investment & Private Equity Firms : Investors require detailed UK market analysis to evaluate acquisition targets, assess growth potential, and make informed capital allocation decisions in the animal health sector.
    • Veterinary Practice Networks : Veterinary clinics and hospital chains need market insights to understand product demand trends, procurement opportunities, and emerging biologics to enhance service offerings.
    • Government & Regulatory Bodies : UK health authorities and agricultural departments require market intelligence for policy development, biosecurity planning, and animal health surveillance initiatives.
    • Research & Academic Institutions : Universities and research centers need market data to align R&D initiatives with commercial opportunities and identify collaboration potential with industry stakeholders.

    Key Companies in the UK Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Reasons to Buy this Report

    • Market-Specific Insights : Gain detailed analysis of the UK veterinary biologics market with country-specific data, regulatory landscape assessment, and competitive dynamics tailored to the British market.
    • Growth Opportunity Identification : Identify high-potential segments within the UK market, including companion animal biologics, livestock vaccines, and emerging therapeutic areas with the strongest growth trajectories.
    • Regulatory & Compliance Guidance : Understand UK-specific regulatory requirements, MHRA guidelines, and post-Brexit compliance standards essential for market entry and product commercialization strategies.
    • Competitive Landscape Analysis : Access comprehensive competitive intelligence on UK-based and international players operating in the veterinary biologics space, including market share and strategic positioning.
    • Investment & Partnership Strategy : Leverage UK market forecasts and growth projections to inform investment decisions, partnership opportunities, and expansion strategies within the European veterinary sector.

    Frequently asked questions

    What is the current size of the UK veterinary biologics market?

    The UK veterinary biologics market is valued at $75.01 million in 2025 and is expected to grow to $99 million by 2030.

    What is the growth rate of the UK veterinary biologics market?

    The UK veterinary biologics market is projected to grow at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2030.

    What are the main drivers of growth in the UK veterinary biologics market?

    Key drivers include rising pet ownership, increased biosecurity concerns in livestock farming, strong regulatory support, and growing adoption of precision medicine in veterinary care across the UK.

    Which animal segments are driving the UK veterinary biologics market?

    The UK market is driven by demand across companion animals, livestock, and equine segments, with each sector benefiting from advances in biological therapeutics and vaccines.

    How does the UK veterinary biologics market compare to other European markets?

    The UK holds a strong position in Europe due to its advanced veterinary infrastructure, robust regulatory frameworks, and leadership in veterinary research and development.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status